Dyspnea: Applying research to bedside practice

AACN Advanced Critical Care

Volumn 18, Issue 1, 2007, Pages 45-58

  Spector, Nancy ^a   Connolly, Maria A ^b   Carlson, Karen K ^c  

^a NATIONAL COUNCIL OF STATE BOARDS OF NURSING   (United States)

^b UNIVERSITY OF ST FRANCIS   (United States)

^c Carlson Consulting Group   (United States)

Author keywords

Dyspnea; Evidence based practice; Respiratory symptoms

Indexed keywords

ADULT; AGED; ARTIFICIAL VENTILATION; CASE REPORT; CHEMORECEPTOR; DYSPNEA; EVIDENCE BASED MEDICINE; FEMALE; HOSPITALIZATION; HUMAN; INTENSIVE CARE; MALE; MECHANORECEPTOR; METHODOLOGY; NURSE ATTITUDE; NURSING; NURSING ASSESSMENT; ORGANIZATION AND MANAGEMENT; OXYGEN THERAPY; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PATIENT CARE PLANNING; PHYSICAL EXAMINATION; REVIEW; RISK FACTOR;

ADULT; AGED; CHEMORECEPTORS; CRITICAL CARE; DYSPNEA; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MECHANORECEPTORS; NURSE'S ROLE; NURSING ASSESSMENT; OXYGEN INHALATION THERAPY; PALLIATIVE CARE; PATIENT CARE PLANNING; PHYSICAL EXAMINATION; RESEARCH DESIGN; RESPIRATION, ARTIFICIAL; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 33846842187     PISSN: 15597768     EISSN: 15597768     Source Type: Journal    
DOI: 10.1097/01256961-200701000-00006     Document Type: Review

References (98)

1. American Thoracic Society. Dyspnea: mechanisms, assessment, and management: a consensus statement. Am J Respir Crit Care Med. 1999;159:321-340.
2. Lenz ER, Suppe F, Gift AG, Pugh LC, Milligan RA. Collaborative development of middle-range nursing theories: toward a theory of unpleasant symptoms. ANS Adv Nurs Sci. 1995;17:1-13.
3. Lenz ER, Pugh LC, Milligan RA, Gift A, Suppe F. The middle-range theory of unpleasant symptoms: an update. ANS Adv Nurs Sci. 1997;19:14-27.
4. Ripamonti C. Management of dyspnea in advanced cancer patients. Support Care Cancer. 1999;7: 233-243.
5. Runo JR, Ely EW. Treating dyspnea in a patient with advanced chronic obstructive pulmonary disease. Best Pract. 2001;175:197-201.
6. Spector N, Klein D. Chronic critically ill dyspneic patients: mechanisms and clinical measurement. AACN Clin Issues. 2001;12:220-233.
7. Zebraski SE, Kochenash SM, Raffa RB. Minireview. Lung opioid receptors: pharmacology and possible target for nebulized morphine for dyspnea. Life Sci. 2000;66:2221-2231.
8. Carrieri VK, Janson-Bjerklie S, Jacobs S. The sensation of dyspnea: a review. Heart Lung. 1984;13:436-445.
9. Davis C. Palliation of breathlessness. In: von Gunten CF, ed. Palliative Care and Rehabilitation of Cancer Patients. Boston, Mass: Kluwer Publishers; 1999.
10. Curley FJ. Dyspnea. In: Irwin RS, Curley FJ, Grossman RF, eds. Diagnosis and Treatment of Symptoms of the Respiratory Tract. New York, NY: Futura Publishers; 1997:55-115.
11. McCarley C. A model of chronic dyspnea. Image. 1999;31:231-236.
12. Campbell ML. Terminal dyspnea: caring for a patient who refuses intubation or ventilation. Dimens Crit Care Nurs. 1996;15:4-12.
13. Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Chest. 1986;89:234-236.
14. Nelson JE, Meier DE, Oei EJ, et al. Self-reported symptom experience of critically ill cancer patients receiving intensive care. Crit Care Med. 2001;29: 277-282.
15. Lynch MP. Dyspnea. Clin J Oncol Nurs. 2006;10:323-326.
16. Rousseau P. Nonpain symptom management in terminal care. Clin Geriatr Med. 1996;12:313-327.
17. Celli BR. The importance of spirometry in COPD and asthma: effect on approach to management. Chest. 2000;117:15S-19S.
18. Hansen-Flaschen JH. Dyspnea in the ventilated patient: a call for patient-centered mechanical ventilation. Respir Care. 2000;45:1460-1467.
19. Powers J, Bennett SJ. Measurement of dyspnea in patients treated with mechanical ventilation. Am J Crit Care. 1999;8:254-261.
20. Knebel AR, Janson-Bjerklie SL, Malley JD, Wilson AG, Marini JJ. Comparison of breathing comfort during weaning with two ventilatory modes. Am J Respir Crit Care Med. 1994;149:14-18.
21. Bouley GH, Froman R, Shah H. The experience of dyspnea during weaning. Heart Lung. 1992;21:471-476.
22. Manning HL, Schwartzstein RM. Mechanisms of dyspnea. In: Mahler DA, ed. Dyspnea. New York, NY: Marcel Dekker Inc; 1998.
23. Caruana-Montaldo B, Gleeson K, Zwillich CW. The control of breathing in clinical practice. Chest. 2000;117: 205-225.
24. Sibuya M, Yamada M, Kanamaru A, et al. Effect of chest wall vibration on dyspnea in patients with chronic respiratory disease. Am J Respir Crit Care Med. 1994;149: 1235-1240.
25. Chen ZF, Eldridge L, Wagner PG. Respiratory-associated thalamic activity is related to level of respiratory drive. Respir Physiol. 1992;90:99-113.
26. Schwartzstein RM. Language of dyspnea. In: Mahler DA, O'Donnell DE, eds. Dyspnea. Boca Raton, Fla: Taylor & Francis; 2005.
27. Morgan WC, Hodge HL. Diagnostic evaluation of dyspnea. Am Fam Physician [serial online]. February 15, 1998. Available at: http://www.aafp.org/afp/980215ap/morgan.html. Accessed December 27, 2006.
28. Mahler DA. Measurement of dyspnea: clinical ratings. In: Mahler DA, O'Donnell DE, eds. Dyspnea. Boca Raton, Fla: Taylor & Francis; 2005.
29. Van der Molen B. Dyspnea: a study of measurement instruments for the assessment of dyspnea and their application for patients with advanced cancer. J Adv Nurs. 1995;22:948-956.
30. Aitken RCB. Measurement of feelings using visual analog scales. Proc Royal Soc Med. 1969;62: 989-993.
31. Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehab Med. 1970;2:92-98.
32. Wong DL, Baker CM. Reference Manual for the Wong-Baker Faces Pain Rating Scale. Duarte, Calif: Mayday Pain Resource Center; 1991.
33. Ferraresi V. Inhaled opioids for the treatment of dyspnea. Am J Health-Syst Pharm. 2005;62:319-320.
34. Jennings AL, Davies AN, Higgins JP, et al. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database Syst Rev. 2001;4:CD002066.
35. Polosa R, Simidchiev A, Walters EH. Nebulised morphine for severe interstitial disease. Cochrane Database Syst Rev. 2002;3:CD002872.
36. Rushby I, Scullion J. Managing dyspnea in end-stage chronic obstructive pulmonary disease (COPD). Prim Health Care. 2004;14:43-49.
37. Booth S, Kelly MJ, Cox NP, Adams L, Guz A. Does oxygen help dyspnea in patients with cancer? Am J Respir Crit Care Med. 1996;153:1515-1518.
38. Cherniack N. Chronic Obstructive Pulmonary Disease. Philadelphia, Pa: WB Saunders; 1991.
39. Gosselink RA, Wagenaar RC, Rijswijk H, Sargeant AJ, Decramer ML. Diaphragmatic breathing reduces efficiency of breathing in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995; 151:1136-1142.
40. Gift A, Moore T, Soeken K. Relaxation to reduce dyspnea and anxiety in COPD patients. Nurs Res. 1992;41: 242-246.
41. Renfroe KL. Effect of progressive relaxation on dyspnea and state anxiety in patients with chronic obstructive pulmonary disease. Heart Lung. 1988;17:408-413.
42. Pan CX, Morrison R, Ness J, Fugh-Berman A, Leipzig RM. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life: a systematic review. J Pain Symptom Manage. 2000;20:374-387.
43. Allard P, Lamontagne C, Bernard P, Tremblay C. How effective are supplementary doses of opioids for dyspnea in terminally ill cancer patients? A randomized continuous sequential clinical trial. J Pain Symptom Manage. 1999;17:256-265.
44. Ho SF, O'Mahoney MS, Steward JA, Breay P, Buchalter M, Burr ML. Dyspnoea and quality of life in older people at home. Age Ageing. 2001;30:155-159.
45. Hospice Nurses Association. Hospice and Palliative Care Clinical Practice Protocol: Dyspnea. Pittsburgh, Pa: Hospice and Palliative Nurses Association; 1996: 1-28.
46. Knebel AR. Dyspnea in the ventilator-assisted patient: evaluation and treatment. In: Mahler DA, ed. Dyspnea. New York, NY: Marcel Dekker Inc; 1998.
47. Birks C. Pathophysiology and management of dyspnoea in palliative care and the evolving role of the nurse. Int J Palliat Nurs. 1997;3:264-274.
48. Hardie GE, Janson S, Gold W, Carrieri-Kohlman V, Boushey H. Ethnic differences: word descriptors used by African-American and white asthma patients during induced bronchoconstriction. Chest. 2000;117:935-943.
49. Harver A, Mahler DA, Schwartzstein RM, Baird JC. Descriptors of breathlessness in healthy individuals: distinct and separable constructs. Chest. 2000;118:679-690.
50. Lanuza D, Lafaiver C, McCabe M, Farcas GA, Garrity E Jr. Prospective study of functional status and quality of life before and after lung transplantation. Chest. 2000;118:115-122.
51. Casaburi R. Exercise training in chronic obstructive lung disease. In: Casaburi R, Petty TL, eds. Principles and Practice of Pulmonary Medicine. Philadelphia, Pa: WB Saunders; 1993.
52. Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest. 1994; 105:1411-1419.
53. Congleton J, Muers MF. The incidence of airflow obstruction in bronchial carcinoma, its relation to breathlessness, and response to bronchodilator therapy. Respir Med. 1995;89:291-296.
54. Luce JM, Luce JA. Management of dyspnea in patients with far-advanced lung disease: "Once I lose it, it's kind of hard to catch it..." JAMA. 2001;285:1331-1337.
55. O'Donnell DE, Webb KA, Bertley J, Chau L, Conian A. Mechanisms of relief of exertional breathlessness following unilateral bullectomy and lung volume reduction surgery in emphysema. Chest. 1996;110:18-27.
56. Ottanelli R, Rosi E, Romagnoli I, et al. Do inhaled corticosteroids affect perception of dyspnea during bronchoconstriction in asthma? Chest. 2001;120:770-777.
57. Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest. 1997;112:336-340.
58. Reid RT, Rudd RM. Management of malignant pleural effusion. Thorax. 1993;48:779-780.
59. Tanigawa N, Sawada S, Okuda Y, Kobayashi M, Mishima K. Symptomatic improvement in dyspnea following tracheobronchial metallic stenting for malignant airway obstruction. Acta Radiol. 2000;41:425-428.
60. Wong PS, Goldstraw P. Pleuroperitoneal shunts. Br J Hosp Med. 1991;50:16-21.
61. Yusen RD, Lefrak SS, Trulock EP. Evaluation and preoperative management of lung volume reduction surgical candidates. Clin Chest Med. 1997;18:199-224.
62. Dudgeon D. Management of dyspnea at the end of life. In: Mahler DA, O'Donnell DE, eds. Dyspnea. Boca Raton, Fla: Taylor & Francis; 2005.
63. Boyd KJ, Kelly M. Oral morphine as symptomatic treatment of dyspnoea in patients with advanced cancer. Palliat Med. 1997;11:277-281.
64. Bruera E, Macmillan K, Pither J, MacDonald RN. Effects of morphine on dyspnea of terminal cancer patients. J Pain Symptom Manage. 1990;5:341-344.
65. Farncombe M, Chater S. The use of nebulized opioids for breathlessness: a chart review. Palliat Med. 1994;8:306-312.
66. Light RW, Muro JR, Sato RI, Stansbury DW, Fischer CE, Brown SE. Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1989;139:126-133.
67. Mazzocato C, Buclin T, Rapin CH. The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer: a randomized double-blind controlled trial. Ann Oncol. 1999;10:1511-1514.
68. Poole PJ, Veale AG, Black PN. The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. J Respir Crit Care Med. 1998;157:1877-1880.
69. Tanaka K, Shima Y, Kakinuma R, et al. Effect of nebulized morphine in cancer patients with dyspnea: a pilot study. Jpn J Clin Oncol [serial online]. 1999;29:600-603. Available at: http://jjco.oxfordjournals.org/cgi/ content/full/29/12/600. Accessed December 27, 2006.
70. Noseda A, Carpiaux JP, Markstein C, Meyvaert A, de Maertelaer V. Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. Eur Resp J. 1997;10:1079-1083.
71. Argyropoulou P, Patakas D, Koukou A, Vasiliadis P, Georgopoulos D. Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiration. 1993;60: 216-220.
72. Cowcher K, Hanks GW. Long-term management of respiratory symptoms in advanced cancer. J Pain Symptom Manage. 1990;5:320-328.
73. Man GC, Hsu K, Sproule BJ. Effect of alprazolam on exercise and dsypnea in patients with chronic obstructive pulmonary disease. Chest. 1986;90:836-836.
74. McIver B, Walsh D, Nelson K. The use of chlorpromazine for symptom control in dying cancer patients. J Pain Symptom Manage. 1994;9:341-345.
75. Woodcock AA, Gross ER, Geddes DM. Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. Br Med J. 1981;283:343-345.
76. Bruera E, de Stoutz N, Velasco-Leiva A, Schoeller T, Hanson J. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet. 1993;342:13-14.
77. Dewan NA, Bell CW. Effect of low-flow and high-flow oxygen delivery on exercise tolerance and sensation of dyspnea: a study comparing transtracheal catheter and nasal prongs. Chest. 1994;105:1061-1065.
78. Garrod PR, Wedzicha JA. Supplemental oxygen during pulmonary rehabilitation in patients with COPD with exercise hypoxaemia. Thorax. 2000;55:539-543.
79. Knebel AR, Bentz E, Barnes P. Dyspnea management in alpha-1 antitrypsin deficiency: effect of oxygen administration. Nurs Res. 2000;49:333-338.
80. Moore DP, Weston AR, Hughes JM, Oakley CM, Cleland JG. Effects of increased oxygen concentrations on exercise performance in chronic heart failure. Lancet. 1992;339:850-853.
81. Petty TL, Casaburi R. Recommendations of the fifth oxygen consensus conference. Writing and organizing committees. Respir Care. 2000;45:940-943.
82. Swinburn CR, Mould H, Stone TN, Corris PA, Gibson GJ. Symptomatic benefit of supplemental oxygen in hypoxemic patients with chronic lung disease. Am Rev Respir Dis. 1991;143:913-915.
83. Schwartzstein RM, Lahive K, Pope A, Weinberger SE, Weiss JW. Cold facial stimulation reduces breathlessness induced in normal subjects. Am Rev Respir Dis. 1987;136:58-61.
84. Thompson CL. Dyspnea with and without fan blowing on face of hospitalized adults. Crit Care Med. 2001;29(suppl):A148.
85. Barach AL. Chronic obstructive lung disease: postural relief of dyspnea. Arch Phys Med Rehab. 1974;55: 494-504.
86. Eltayara L, Ghezzo H, Milic-Emili J. Orthopnea and tidal expiratory flow limitation in patients with stable COPD. Chest. 2001;119:99-104.
87. O'Neill S, McCarthy DS. Postural relief of dyspnoea in severe chronic airflow limitation: relationship to respiratory muscle strength. Thorax. 1983;38: 595-600.
88. Sharp JT, Drutz WS, Moisan T, Foster J, Machnach W. Postural relief of dyspnea in severe chronic obstructive pulmonary disease. Am Rev Respir Dis. 1980;122: 201-211.
89. Faling LJ. Pulmonary rehabilitation-physical modalities. Clin Chest Med. 1986;7:599-618.
90. Sinclair JD. The effect of breathing exercises in pulmonary emphysema. Thorax. 1955;10:246-249.
91. Stulbarg MS, Ries AL, Belman MJ. Treatment of dyspnea: physical modalities, oxygen, and pharmacology. In: Mahler DA, ed. Dyspnea. New York, NY: Marcel Dekker; 1998.
92. Tiep BL, Burns M, Kao D, Madison R, Herrara J. Pursed lips breathing training using ear oximetry. Chest. 1986;90:218-221.
93. Carrieri-Kohlman V, Gormley JM. Coping strategies for dyspnea. In: Dyspnea. New York, NY: Marcel Dekker; 1998.
94. Filshie J, Penn K, Ashley S, Davis CL. Acupuncture for the relief of cancer-related breathlessness. Palliat Med. 1996;10:145-150.
95. Jobst K, Chen JH, McPherson J, et al. Controlled trial of acupuncture for disabling breathlessness. Lancet. 1986;2:1416-1419.
96. Maa SH, Gauthier D, Turner M. Acupressure as an adjunct to a pulmonary rehabilitation program. J Cardiopulm Rehabil. 1997;91:320-329.
97. McBride S, Graydon J, Sidani S, Hall L. The therapeutic use of music for dyspnea and anxiety in patients with COPD who live at home. J Holis Nurs. 1999;17:229-250.
98. Carrieri-Kohlman VK, Janson-Bjerklie S. Dyspnea. In: Pathophysiological Phenomena in Nursing: Human Responses to Illness. Philadelphia, Pa: WB Saunders; 1993.